<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03997292</url>
  </required_header>
  <id_info>
    <org_study_id>K201707</org_study_id>
    <nct_id>NCT03997292</nct_id>
  </id_info>
  <brief_title>Intravenous Thrombolysis Registry for Acute Ischemic Stroke in China</brief_title>
  <official_title>Intravenous ThrombolysisRegistry for Acute Ischemic Stroke in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General Hospital of Shenyang Military Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General Hospital of Shenyang Military Region</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To analyze the real situation of intravenous thrombolysis in acute ischemic stroke in China
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Compare the efficacy and safety of different thrombolytic drugs; Analysis of patients during
      hospital treatment of adverse events and complications; Analysis of factors that affect the
      effectiveness of treatment; Evaluate the pharmacological benefits of different thrombolytic
      drugs
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The study has been terminated due to key change of protocol
  </why_stopped>
  <start_date type="Anticipated">March 1, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>mRS of 90 days after thrombolysis</measure>
    <time_frame>Month 3</time_frame>
    <description>Proportion of patients with mRS = 0-1 points 90 days after thrombolysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Adverse events</measure>
    <time_frame>Year 1</time_frame>
    <description>Symptomatic intracranial hemorrhage conversion rate; Liver and kidney dysfunction; Bleeding gums; Skin mucous membrane bleeding</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Economic evaluation</measure>
    <time_frame>Day 14</time_frame>
    <description>The cost-effectiveness of different thrombolytic drugs</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Alteplase group</arm_group_label>
    <description>According to 0.6-0.9mg / kg alteplase (maximum can not exceed 90mg), of which 10% intravenous injection, the remaining 60 minutes intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Urokinase group</arm_group_label>
    <description>1.2-1.5 million U dissolved in 100ml sodium chloride injection, 30 minutes intravenously End</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alteplase</intervention_name>
    <description>According to 0.6-0.9mg / kg alteplase (maximum can not exceed 90mg), of which 10% intravenous injection, the remaining 60 minutes intravenous infusion.</description>
    <arm_group_label>Alteplase group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Urokinase</intervention_name>
    <description>1.2-1.5 million U dissolved in 100ml sodium chloride injection, 30 minutes intravenously.</description>
    <arm_group_label>Urokinase group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Thrombolytic patients with acute ischemic stroke within 3 hours of onset
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1) age&gt; 18 years old;

          -  2) meet the diagnostic criteria of China 2014 guidelines for the diagnosis and
             treatment of acute ischemic stroke;

          -  3) no history of first sepsis or previous cerebral infarction sequelae (mRS ≤ 1);

          -  4) within 3 hours of onset;

          -  5) Have measurable neurological deficits;

          -  6) Patients or legal guardians can understand and sign informed consent.

        Exclusion Criteria:

          -  Absolute exclusion criteria:

          -  1) history of head trauma or stroke within the last 3 months;

          -  2) suspected subarachnoid hemorrhage;

          -  3) history of previous intracranial hemorrhage;

          -  4) intracranial tumor, arteriovenous malformation or aneurysm ;

          -  5) recent intracranial or intraspinal surgery;

          -  6) arterial puncture at an incurable site within the last 7 days;

          -  7) elevated blood pressure: systolic blood pressure ≥180 mm Hg, or diastolic blood
             pressure ≥100 mm Hg;

          -  8) Internal bleeding;

          -  9) acute bleeding tendency, including platelet count less than 100 × 109 / L or other
             conditions;

          -  10) heparin treatment within 48 h (APTT is outside the upper limit of normal range);

          -  11) oral anticoagulant, INR&gt; 1.7 Or PT&gt; 15S;

          -  12) are currently using thrombin inhibitors or factor Xa inhibitors, various sensitive
             laboratory abnormalities (such as APTT, INR, platelet count, ECT; TT or appropriate
             factor Xa activity assays) ;

          -  13) Blood glucose &lt;50 mg / dl (2.7 mmol / L);

          -  14) CT suggestive of multiple cerebral infarction (low density range&gt; 1/3 of the
             cerebral hemispheres) ;

          -  15) Other conditions considered unsuitable for inclusion in this clinical study;

          -  16) 3 months or are participating in other clinical trials;

          -  17) combined with severe systemic disease is expected to survive less than three
             months.

          -  Relative exclusion criteria:

          -  1) severe stroke (NIHSS&gt; 25 points);

          -  2) pregnancy;

          -  3) neurological deficits after epileptic seizures;

          -  4) major surgery or severe trauma within the last 14 days;

          -  5) Urethral hemorrhage;

          -  6) Myocardial infarction within the last 3 months;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huisheng Chen, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurology Chief</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>General Hospital of Shenyang Military Region</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>November 14, 2017</study_first_submitted>
  <study_first_submitted_qc>June 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2019</study_first_posted>
  <last_update_submitted>June 21, 2019</last_update_submitted>
  <last_update_submitted_qc>June 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>General Hospital of Shenyang Military Region</investigator_affiliation>
    <investigator_full_name>Hui-Sheng Chen</investigator_full_name>
    <investigator_title>Neurology Chief</investigator_title>
  </responsible_party>
  <keyword>alteplase; urokinase; intravenous thrombolysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

